JP2011516478A5 - - Google Patents

Download PDF

Info

Publication number
JP2011516478A5
JP2011516478A5 JP2011502995A JP2011502995A JP2011516478A5 JP 2011516478 A5 JP2011516478 A5 JP 2011516478A5 JP 2011502995 A JP2011502995 A JP 2011502995A JP 2011502995 A JP2011502995 A JP 2011502995A JP 2011516478 A5 JP2011516478 A5 JP 2011516478A5
Authority
JP
Japan
Prior art keywords
composition
subject
effective
cytostatic
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/002134 external-priority patent/WO2009145841A1/en
Publication of JP2011516478A publication Critical patent/JP2011516478A/ja
Publication of JP2011516478A5 publication Critical patent/JP2011516478A5/ja
Pending legal-status Critical Current

Links

JP2011502995A 2008-04-03 2009-04-03 免疫療法のための組成物および方法 Pending JP2011516478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4221008P 2008-04-03 2008-04-03
US61/042,210 2008-04-03
PCT/US2009/002134 WO2009145841A1 (en) 2008-04-03 2009-04-03 Compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
JP2011516478A JP2011516478A (ja) 2011-05-26
JP2011516478A5 true JP2011516478A5 (enExample) 2012-05-24

Family

ID=41267359

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502995A Pending JP2011516478A (ja) 2008-04-03 2009-04-03 免疫療法のための組成物および方法

Country Status (12)

Country Link
US (5) US20090281047A1 (enExample)
EP (1) EP2271350A4 (enExample)
JP (1) JP2011516478A (enExample)
CN (1) CN102046180A (enExample)
AU (1) AU2009251848A1 (enExample)
CA (1) CA2757437A1 (enExample)
IL (1) IL208445A0 (enExample)
MX (1) MX339451B (enExample)
NZ (1) NZ588668A (enExample)
RU (1) RU2010144744A (enExample)
WO (1) WO2009145841A1 (enExample)
ZA (1) ZA201007830B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
BRPI0923164A2 (pt) 2008-12-19 2016-01-26 Graceway Pharmaceuticals Llc formulações de imiquimod com concentração de dosagem menos e regimes de dosagem curtos para o tratamento de ceratose actínica.
GEP20156418B (en) 2009-07-13 2016-01-11 Medicis Pharmaceutical Corp Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
EP3056201A1 (en) * 2010-06-07 2016-08-17 Abraxis BioScience, LLC Combination therapy methods for treating proliferative diseases
US20130171279A1 (en) * 2012-01-04 2013-07-04 Physicianrx, Llc Composition for Reducing Side- and After-Effects of Cancer Treatment
CN103156951A (zh) * 2013-04-11 2013-06-19 太仓市胜舟生物技术有限公司 一种治疗b细胞淋巴瘤的组合药物
WO2015107375A1 (es) * 2013-12-20 2015-07-23 Vergara Campillo Ramiro Moises Combinación de piridoxina, ácido fólico y iones de magnesio para el tratamiento del cáncer
AU2017214668B2 (en) 2016-02-04 2022-12-08 Auransa, Inc. Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
WO2018027029A1 (en) * 2016-08-03 2018-02-08 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
WO2019032411A1 (en) * 2017-08-07 2019-02-14 Cognate 3 Llc COMPOSITIONS AND METHODS FOR INDUCING APOPTOSIS IN ANAEROBIC CELLS AND ASSOCIATED CLINICAL METHODS FOR THE TREATMENT OF CANCER AND PATHOGENIC INFECTIONS
WO2022200833A1 (en) * 2021-03-25 2022-09-29 2B-Shvat Ltd. Benzaldehyde extracted from rosales as foodstuff preservative, animal-feed additive, and for treatment of the covid-19 virus
JP7018531B1 (ja) 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
US20250161234A1 (en) * 2022-02-24 2025-05-22 Shmuel ROBINOV Methods of use of benzaldehyde compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882314A (en) * 1985-12-02 1989-11-21 Rikagaku Kenkyusho A composition and method of treating selected malignant conditions
US6407071B1 (en) * 1998-06-04 2002-06-18 Co-Enzyme Technology Ltd. Method and composition for treating malignant cells
NO309305B1 (no) * 1999-02-19 2001-01-15 Norsk Hydro As Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater

Similar Documents

Publication Publication Date Title
JP2011516478A5 (enExample)
RU2010144744A (ru) Композиции и способы иммунотерапии
US11730736B2 (en) Anticancer agents
JP2020514271A5 (enExample)
RU2018120318A (ru) ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
KR101575706B1 (ko) 암 치료용 선택적인 ｅｐ４ 수용체 길항제
JP2021191750A5 (enExample)
AU2010234968B2 (en) Treatment regimen utilizing neratinib for breast cancer
RU2018142394A (ru) Композиции и способы для лечения нейтропении
JP2012153722A5 (enExample)
JP2014510729A5 (enExample)
JP6198286B2 (ja) 癌の処置のためのイソフラボノイド化合物および方法
JP2012158602A5 (enExample)
HRP20220351T1 (hr) 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene
JP2018517686A5 (enExample)
ES2877712T3 (es) Terapias combinadas para su uso en el tratamiento del cáncer de mama
JP2013531068A (ja) ４−ヨード−３−ニトロベンズアミドを抗腫瘍剤と組み合わせて用いる乳癌の治療方法
JP2017505785A5 (enExample)
JP2012522841A5 (enExample)
JP2020514344A5 (enExample)
AU2022409798A1 (en) Use of combination therapy for treating cancer
SI3174881T1 (en) (1,2,4) triazolo (4,3-B) pyridazines for use in the treatment of proliferative diseases
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
JP2019525924A5 (enExample)
JP2005509663A5 (enExample)